BNTC
Benitec Biopharma Inc.BS score 51.6MEDIUMPHASE2 · mkt cap $377.1M · rev ttm $0
drug hypothesis
BB-301 modulates Unknown - not disclosed in provided trial data to treat Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia.
moa:Unknown - not disclosed in provided trial data. Gene therapy approach implied by intramuscular administration and context of muscular dystrophy.
score breakdown
trial design70
base rate disconnect9
language red flags100
composite51.6
valuation analysis
market cap$377.1M
revenue ttm$0
phasePHASE2
historical base rate25%
disconnect ratio0.3x
lead trialNCT06185673
meta
cik0001808898
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1/2a, non-randomized, open-label, not placebo-controlled, dose-escalation study. Enrollment: 30 subjects. Administered via intramuscular injection. Primary completion expected November 2030.
primary endpoint:Incidence of dose-limiting toxicities (DLTs) in phase 1b (up to 60 days)
claimed differentiation
Not stated in provided data
language red flags
- Very long trial timeline (2023-2030) for a Phase 1 study
- Primary endpoint is safety (DLTs) rather than efficacy - standard for early phase but indicates early stage
- No efficacy endpoint listed as primary - all secondary
- Trial design is non-randomized, non-placebo-controlled which limits interpretability of efficacy signals
- Target and mechanism not disclosed in trial registration data
company-stated risks
- Typical gene therapy risks (immunogenicity, off-target effects) - not explicitly stated in data
- Dose-limiting toxicity monitoring indicates safety concern
upcoming catalysts
- 2030-11Phase 1b primary completion
- 2030-11Phase 2a completion